Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 14/20 | 0.51 |
| ▸ | HTR2B | P41595 | 13/20 | 0.51 |
| ▸ | HTR2A | P28223 | 12/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11639039 | 0.85 | HTR2C (0.58) | HTR2CHTR2BHTR2ASIGMAR1 | |
| SCHEMBL6646375 | 0.80 | GRIN2B (0.55) | HTR2CHTR2BHTR2ATAAR1 | |
| SCHEMBL13595398 | 0.79 | TAAR1 (0.44) | HTR2CHTR2BHTR2ATAAR1 | |
| Hydrochloric Acid SCHEMBL7511833 | 0.79 | HTR2C (0.42) | HTR2CHTR2BHTR2A | |
| SCHEMBL13119261 | 0.79 | HTR2C (0.53) | HTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL2224880 | 0.78 | HPGD (0.54) | HTR2CHTR2BHTR2ATAAR1 | |
| SCHEMBL29501433 | 0.77 | SLC18A3 (0.50) | HTR2CHTR2BHTR2ATAAR1 | |
| SCHEMBL14069048 | 0.77 | HTR2C (0.46) | HTR2CHTR2BHTR2ATAAR1 | |
| SCHEMBL13595219 | 0.76 | TAAR1 (0.42) | HTR2CHTR2BHTR2ATAAR1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL4410185 | 0.75 | TAAR1 (0.41) | HTR2CHTR2BHTR2ATAAR1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550475-B2 | Condensed polycyclic compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-06-23 | — | — | US | disclosed |
| US-7550476-B2 | Condensed polycyclic compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-06-23 | — | — | US | disclosed |
| US-7550464-B2 | Use of phosphodiesterase 4 inhibitors such as 8,9-dimethoxy-6-phenyl-1,3,4,6,11,11a-hexahydro-2H -pyrazino[1,2-b]isoquinoline for treating asthma, chronic obstructive pulmonary disease, atopic dermatitis, allergic rhinitis, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis | MITSUBISHI TANBE PHARMA CORPORATION (JP) | 2009-06-23 | — | — | US | disclosed |
| EP-1424326-B1 | FUSED-POLYCYCLIC COMPOUNDS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-05-28 | — | — | EP | disclosed |
| EP-1746100-A1 | ANNELATED CARBAMOYLASE-HETEROCYCLES, FOCUSED LIBRARY, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE PRODUCTION THEREOF | "Chemical diversity Research Institute", Ltd. (RU) | 2007-01-24 | — | — | EP | disclosed |
| US-20070010521-A1 | Condensed polycyclic compounds | TANABE SEIYAKU CO., LTD. | 2007-01-11 | — | — | US | disclosed |
| US-20070004739-A1 | Condensed polycyclic compounds | TANABE SEIYAKU CO., LTD. | 2007-01-04 | — | — | US | disclosed |
| US-20070004740-A1 | Condensed polycyclic compounds | TANABE SEIYAKU CO., LTD. | 2007-01-04 | — | — | US | disclosed |
| US-7153859-B2 | Condensed polycyclic compounds | TANABE SEIYAKU CO., LTD. (JP) | 2006-12-26 | — | — | US | disclosed |
| US-20040204418-A1 | Fused-polycyclic compounds | TANABE SEIYAKU CO., LTD. (JP) | 2004-10-14 | — | — | US | disclosed |
| EP-1424326-A1 | FUSED-POLYCYCLIC COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2004-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004740-A1 | Condensed polycyclic compounds | PDE4A, PDE4B, PDE3B | HTR2C 2836/4885HTR2B 2254/4885HTR2A 3638/4885 |
| US-20070010521-A1 | Condensed polycyclic compounds | PDE4A, PDE4B, PDE3B | HTR2C 2836/4885HTR2B 2254/4885HTR2A 3638/4885 |
| US-20070004739-A1 | Condensed polycyclic compounds | PDE4A, PDE4B, PDE3B | HTR2C 2836/4885HTR2B 2254/4885HTR2A 3638/4885 |
| US-20040204418-A1 | Fused-polycyclic compounds | PDE4A, PDE4B, PDE3B | HTR2C 3379/4885HTR2B 2925/4885HTR2A 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.